Forecasting outcomes in anti-NMDAR encephalitis
Clearer prognostic markers needed
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
“It's dangerous to make forecasts, especially about the future.” Mark Twain's words hold true in many situations in medicine, particularly in critical illnesses that carry both risk of death and the chance of full recovery, exemplified by autoimmune encephalitis. A decade ago, the description of a unique syndrome of severe encephalitis associated with immunoglobulin G autoantibodies against the NMDA receptor (NMDAR) subtype 1 in young women with ovarian teratoma caught the attention of those interested in paraneoplastic syndromes, but it was considered rare.1 Only 5 years later, it had become clear that this type of encephalitis spanned the spectrum of age and occurred in both sexes; and anti-NMDAR encephalitis (ANE) was now recognized as one of the most frequently occurring encephalitides in patients younger than 40 years of age with unknown etiologies.2 In general, the disease takes a stepwise course with a prodromal state of irritability or depressive mood, then evolves to a limbic encephalitis with memory decline, psychosis, impaired consciousness/coma, and seizures, including status epilepticus. In addition, adventitious movements, including orofacial dyskinesias, and autonomic dysfunction with hypoventilation and blood pressure instability may occur later in the course and pose a substantial risk of prolonged and severe sequelae.3 Patients may need intensive care unit support for ventilation and treatment of refractory status epilepticus, or specific treatment for psychotic behavior.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 130
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.